<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878537</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-17-7057</org_study_id>
    <nct_id>NCT03878537</nct_id>
  </id_info>
  <brief_title>Recurrence Monitoring in NSCLC Using Circulating Tumor DNA</brief_title>
  <official_title>Recurrence Monitoring in NSCLC Using Circulating Tumor DNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scripps Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lexent Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Scripps Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is investigating the role of cell free tumor DNA profiling in determining
      disease relapse and/or progression for patients with advanced NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to determine the ability of cell free tumor DNA genomic
      profiling to predict disease relapse or progression while on therapy for advanced stage NSCLC
      in comparison to current standard objective measures of disease relapse or progression.

      This study is a prospective observational study. The investigators will assess whole genome
      sequencing from patient blood samples collected alongside routine blood draws with each
      treatment cycle to determine the tumor load score at each timepoint while on therapy. CT
      images will be obtained at routinely ordered timepoints throughout therapy and will be used
      in the assessment for standard clinical or radiographic evidence of disease progression.
      These methods of measuring disease progression will be compared in a lead time analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Cell free tumor DNA based PFS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Clinical or radiographic based PFS</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 18 or older with NSCLC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment na√Øve biopsy confirmed not surgically resectable stage III or greater NSCLC

          -  Baseline CT imaging available

        Exclusion Criteria:

          -  Patients unable to undergo biopsy for initial tissue diagnosis

          -  Patients who do not wish to pursue standard of care therapy

          -  Patients with another diagnosis of malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marin Xavier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shannon Fortin Ensign</last_name>
    <phone>858-784-2157</phone>
    <email>FortinEnsign.Shannon@scrippshealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marin Xavier</last_name>
    <phone>619-849-4469</phone>
    <email>Xavier.Marin@scrippshealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scripps Health/Scripps Clinic Hillcrest/Scripps Clinic Torrey Pines</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marin Xavier</last_name>
      <phone>619-849-4469</phone>
      <email>Xavier.Marin@scrippshealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Shannon Fortin Ensign</last_name>
      <phone>858-784-2157</phone>
      <email>FortinEnsign.Shannon@scrippshealth.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scripps Translational Science Institute</investigator_affiliation>
    <investigator_full_name>Shannon Fortin Ensign, MD/PhD</investigator_full_name>
    <investigator_title>Clinical Scholar</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

